Phathom Pharmaceuticals (PHAT) Stock Overview
A biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PHAT Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Phathom Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.73 |
| 52 Week High | US$19.50 |
| 52 Week Low | US$2.21 |
| Beta | 0.44 |
| 1 Month Change | 12.45% |
| 3 Month Change | 63.84% |
| 1 Year Change | -27.51% |
| 3 Year Change | 34.87% |
| 5 Year Change | -67.15% |
| Change since IPO | -44.19% |
Recent News & Updates
Recent updates
Phathom Pharmaceuticals: The IP Question Is Answered, But Can Management Deliver (Rating Upgrade)
Sep 08Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Jul 19
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump
Jun 02
Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity
Phathom focuses on VOQUEZNA's market potential in GERD treatment to drive substantial revenue while aiming for profitability through strategic cost management.Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Apr 18Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable
Dec 11Following Up On Phathom Pharmaceuticals
Sep 03Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Jun 26Phathom: Undervalued Biotech With Possible GERD Treatment Label Expansion
Mar 18Phathom Pharmaceuticals GAAP EPS of -$1.33 misses by $0.30
Aug 02The Prognosis For Phathom Pharmaceuticals
Jun 22Shareholder Returns
| PHAT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.6% | 2.1% | -0.9% |
| 1Y | -27.5% | 3.8% | 20.1% |
Return vs Industry: PHAT underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: PHAT underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| PHAT volatility | |
|---|---|
| PHAT Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PHAT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PHAT's weekly volatility has decreased from 19% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 427 | Steve Basta | www.phathompharma.com |
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc. Fundamentals Summary
| PHAT fundamental statistics | |
|---|---|
| Market cap | US$943.73m |
| Earnings (TTM) | -US$274.55m |
| Revenue (TTM) | US$147.19m |
Is PHAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHAT income statement (TTM) | |
|---|---|
| Revenue | US$147.19m |
| Cost of Revenue | US$18.77m |
| Gross Profit | US$128.42m |
| Other Expenses | US$402.97m |
| Earnings | -US$274.55m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.94 |
| Gross Margin | 87.25% |
| Net Profit Margin | -186.53% |
| Debt/Equity Ratio | -137.4% |
How did PHAT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 05:17 |
| End of Day Share Price | 2025/11/03 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Phathom Pharmaceuticals, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |